Scinai Immunotherapeutics Ltd. has completed a corporate reorganization that separates its contract development and manufacturing activities from its internal research and development operations. The restructuring follows Scinai’s previously announced acquisition of Recipharm Israel Ltd. and is intended to create clearer operational focus across its businesses. Under the new structure, all CDMO‑related operations, including personnel, infrastructure, manufacturing facilities and customer cont...